Skip to main content
Equibles

FRNM · Freenome, Inc. · Documents

Track FRNM — free

Use FRNM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FRNM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.61 -0.95 (-8.22%) At close · Nov 12
Rebalance outlook locked
Going-concern doubt — flagged Jul 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company's liquidity condition and mandatory liquidation raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued. Management plans to address this uncertainty through a Business Combination. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Combination Period. The Company intends to complete the initial Business Combination before the end of the Combination Period. However, there can be no assurance that the Company will be able to consummate any Business Combination by the end of the Combination Period, including if the combination Period is further extended upon approval of the Extension Amendment Proposal.”
View the 10-Q filed Jul 15, 2026
Market Cap
$109.43M
Shares
10.31M
Volume · Nov 12 904.31K Avg daily vol (3M) 861.18K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report Ended Dec 31, 2025 Net income $837.47K 10-K filed Mar 12, 2026 Quarterly report New FY2026 Q3 Revenue $183.49M up 17628.4% 10-Q filed Nov 12, 2026 Latest results New Financial results 8-K filed Nov 10, 2026
2026
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA approval drives revenue and quarterly profit

Freenome reported $182.5 million of third-quarter collaboration revenue and quarterly net income after SimpleScreen CRC received FDA approval, triggering $180.0 million of revenue recognition. The nine-month net loss was $72.5 million.

Revenue $183.49M ▲ 17628.4% Net income $60.11M Diluted EPS $0.58
Read from the MD&A section
6 source passages
This discussion and analysis of Freenome, Inc.’s (“Freenome,” “we,” “us” and “our”) financial condition and results of operations In July 2026, the U.S. Food and Drug Administration (“FDA”) approved SimpleScreen™ CRC, our blood-based colorectal cancer (“CRC”) screening test for adults 45 years of age and older at average risk. License and collaboration revenue was $182.5 million for the three months ended September 30, 2026, compared with no revenue for the same period in 2025. The increase was primarily driven by $180.0 million of revenue recognized under our collaboration agreement with Exact following FDA approval of SimpleScreen CRC in July 2026. Net income (loss) | 60,110 | (64,469) | (72,478) | (181,074) Our net losses were $72.5 million for the nine months ended September 30, 2026. Open the document at this passage
Oct 20
Current report 8-K
Regulation FD disclosure, Other events

Freenome launched SimpleScreen Lung, enabling eligible patients to receive lung and colorectal cancer screening through a single blood draw. The lung test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value.

Jul 9
Current report 8-K
Other events AI summary on its way
May 14
Proxy statement DEF 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
May 5
Proxy statement PRE 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
2025
2024
Showing 1–32 of 32 documents
Key facts CIK 2017526 CUSIP 35661P100 13F (30d) 22 filings 22 filers Visit website